Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China

Virology Journal

FengCai Zhu⁴  Hua Wang⁴  MingHao Zhou⁴  FenYang Tang⁴  WenBo Xu²  Qiang Ding³  MingLei Zhang¹  XiaoQin Chen¹  ZhenYu Zhang¹  JianGuang Fu⁴  Bin Wu⁴  JianLi Hu⁴  XuShan Wang³  HengMing Ge¹  YanMing Liu²  Liang Li⁴  Hong Ji⁴ 

[1] Donghai County Center for Disease Control and Prevention, Jingdu Road, Niushan Town, Donghai County, Lianyungang City, Jiangsu Province, China;Chinese Center for Disease Control and Prevention, No.155, Changbai Road, Changping District, Beijing 102206, China;Ganyu County Center for Disease Control and Prevention, Huanghai Road, Qingkou Town, Ganyu County, Lianyungang City, Jiangsu Province, China;Jiangsu Provincial Center for Disease Control and Prevention, No.172, Jiangsu Road, Gulou District, Nanjing, 210009 Jiangsu Province, China

关键词: Seroepidemiology;    Hand, foot and mouth disease;    Neutralizing antibody;    Maternally-acquired immunity;    CoxsackievirusA16;    Human enterovirus71;   

Others  :  1153370
DOI  :  10.1186/1743-422X-9-248

 received in 2011-12-22, accepted in 2012-09-25,  发布年份 2012

【 摘 要 】

Background

The major etiology of hand, foot and mouth disease (HFMD) is infection with human enterovirus A (HEV-A). Among subtypes of HEV-A, coxsackievirusA16 (CoxA16) and enterovirus 71 (EV71) are major causes for recurrent HFMD among infants and children in Jiangsu Province, mainland China. Here, we analyzed maternal antibodies between prenatal women and their neonates, to determine age-specific seroprevalence of human EV71 and CoxA16 infections in infants and children aged 0 to 15 years. The results may facilitate the development of immunization against HFMD.

Methods

This study used cross-section of 40 pairs of pregnant women and neonates and 800 subjects aged 1 month to 15 years old. Micro-dose cytopathogenic effects measured neutralizing antibodies against EV71 and CoxA16. Chi-square test compared seroprevalence rates between age groups and McNemar test, paired-Samplest-test and independent-samples t-test analyzed differences of geometric mean titers.

Results

A strong correlation between titers of neutralizing antibody against EV71 and CoxA16 in prenatal women and neonates was observed (r_EV71 = 0.67, r_CoxA16 = 0.56, respectively, p < 0.05). Seroprevalence rates of anti-EV71 antibody gradually decreased with age between 0 to 6 months old, remained low between 7 to 11 months(5.0–10.0%), and increased between 1 and 4 years (22.5–87.5%). Age-specific seroprevalence rates of anti-EV71 antibody stabilized in >80% of children between 5 to 15 years of age. However, seroprevalence rates of anti-CoxA16 antibody were very low (0.0–13.0%) between 0 to 6 months of age, gradually increased between 7 months to 4 years (15.0–70.0%), and stabilized at 54.0% (108/200) between 5 to 15 years. Seroprevalence rates against EV71 and CoxA16 were low under 1 year (0.0–10.0%), and showed an age dependent increase with high seroprevalence (52.5–62.5%) between 4 and10 years of age.

Conclusions

Concomitant infection of EV71 and CoxA16 was common in Jiangsu Province. Therefore, development of bivalent vaccine against both EV71 and CoxA16 is critical. The optimal schedule for vaccination may be 4 to11 months of age.

【 授权许可】

   
2012 Ji et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ooi MH, Wong SC, Podin Y, Akin W, del Sel S, Mohan A, Chieng CH, Perera D, Clear D, Wong D, Blake E, Cardosa J, Solomon T: Human Enterovirus 71 Disease in Sarawak, Malaysia: A Prospective Clinical, Virological, and Molecular Epidemiological Study. Clin Infect Dis 2007, 44:646-656.
• [2]Bible JM, Pantelidis P, Chan PK, Tong CY: Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 2007, 17:371-379.
• [3]Yan JJ, Su IJ, Chen PF, Liu CC, Yu CK, Wang JR: Complete Genome Analysis of Enterovirus 71 Isolated from an Outbreak in Taiwan and Rapid Identification of Enterovirus 71and Coxsackievirus a16 by RT-PCR. J Med Virol 2001, 65:331-339.
• [4]Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM: Comparison of enterovirus71, coxsackie-virusA16 clinical illnesses during the Taiwan enterovirus epidemic. Pediatr Infect Dis J 1999, 18:1092-1096.
• [5]Yang KD, Yang MY, Li CC, Lin SF, Chong MC, Wang CL, Chen RF, Lin TY: Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis 2001, 183:850-856.
• [6]Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, Chiang YP, Chiang BL, Lee CY, Huang LM: Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006, 60:466-471.
• [7]Juhela S, Hyöty H, Lönnrot M, Roivainen M, Simell O, Ilonen J: Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol 1998, 54:226-232.
• [8]Yang C, Deng C, Wan J, Zhu L, Leng Q: Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J 2011, 8:306. BioMed Central Full Text
• [9]Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ: Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000, 7:523-528.
• [10]Foo DG, Alonso S, Chow VT, Poh CL: Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007, 9:1299-1306.
• [11]Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, Wang SM, Lei HY, Su IJ, Yu CK: Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007, 81:10310-10315.
• [12]Ooi EE, Phoon MC, Ishak B, Chan SH: Seroepidemiology of Human Enterovirus 71, Singapore. Emerg Infect Dis 2002, 8:995-997.
• [13]Rabenau HF, Richter M, Doerr HW: Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 2010, 199:45-51.
• [14]Tran CB, Nguyen HT, Phan HT, Tran NV, Wills B, Farrar J, Santangelo JD, Simmons CP: The seroprevalence and seroincidence of enterovirus71 infection in infants and children in Ho Chi Minh City. Viet Nam. PLoS One 2011, 6:e21116.
• [15]Luo ST, Chiang PS, Chao AS, Liou GY, Lin R, Lin TY, Lee MS: Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 2009, 15:581-584.
• [16]Gomes Mde L, de Castro CM, Oliveira MJ, da Silva EE: Neutralizing antibodies to enterovirus 71 in Belem, Brazil. Mem Inst Oswaldo Cruz 2002, 97:47-49.
• [17]Hagiwara A, Tagaya I, Komatsu T: Seroepidemiology of enterovirus 71 among healthy children near Tokyo. Microbiol Immunol 1979, 23:121-124.
• [18]Zhu Z, Zhu S, Guo X, Wang J, Wang D, Yan D, Tan X, Tang L, Zhu H, Yang Z, Jiang X, Ji Y, Zhang Y, Xu W: Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol J 2010, 7:300. BioMed Central Full Text
• [19]Chiu CH, Chu C, He CC, Lin TY: Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006, 8:1671-1678.
• [20]Mao QY, Liao XY, Yu X, Li N, Zhu FC, Zeng Y, Liang ZL, Li FX, Wang JZ, Lu FM, Zhuang H: Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin Med J (Engl) 2010, 123:1679-1684.
• [21]Lee MS, Chiang PS, Luo ST, Huang ML, Liou GY, Tsao KC, Lin TY: Incidence rates of enterovirus 71 infections in young children during a nationwide epidemic in Taiwan, 2008–09. PLoS Negl Trop Dis 2012, 6:e1476.
• [22]Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, Huang YC, Shih SR, Chiou ST, Chen PY, Chang HJ, Lin TY: Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002, 109:e88.
• [23]Diedrich S, Weinbrecht A, Schreier E: Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol 2009, 154:1139-1142.
• [24]Castro CM, Cruz AC, Silva EE, Gomes Mde L: Molecular and seroepidemiologic studies of enterovirus 71 infection in the State of Para, Brazil. Rev Inst Med Trop São Paulo 2005, 47:65-71.
• [25]Ho M: Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect 2000, 33:205-216.
• [26]Lu CY, Lee CY, Kao CL, Shao WY, Lee PI, Twu SJ, Yeh CC, Lin SC, Shih WY, Wu SI, Huang LM: Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol 2002, 67:217-223.
• [27]Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT: Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann Acad Med Singapore 2009, 38:106-112.
• [28]Lee MS, Chang LY: Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9:149-156.
• [29]Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71 http://clinicaltrials.gov/ct2/show/NCT01376479 webcite
• [30]A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine http://clinicaltrials.gov/ct2/show/NCT01268787 webcite
• [31]A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants http://clinicaltrials.gov/ct2/show/NCT01391494 webcite
• [32]A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants http://clinicaltrials.gov/ct2/show/NCT01313715 webcite
• [33]Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children http://clinicaltrials.gov/ct2/show/NCT01273246 webcite
• [34]Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults http://clinicaltrials.gov/ct2/show/NCT01273233 webcite
• [35]A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children http://clinicaltrials.gov/ct2/show/NCT01267903 webcite
• [36]Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants http://clinicaltrials.gov/ct2/show/NCT01421121 webcite
• [37]A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants http://clinicaltrials.gov/ct2/show/NCT01399853 webcite
• [38]Huang WC, Huang LM, Kao CL, Lu CY, Shao PL, Cheng AL, Fan TY, Chi H, Chang LY: Seroprevalence of enterovirus 71 and no evidence of crossprotection of enterovirus 71 antibody against the other enteroviruses in kindergarten children in Taipei city. J Microbiol Immunol Infect 2011. in press
• [39]Hsu CH, Lu CY, Shao PL, Lee PI, Kao CL, Chung MY, Chang LY, Huang LM: Epidemiologic and clinical features of non-polio enteroviral infections in northern Taiwan in 2008. J Microbiol Immunol Infect 2011, 44:265-273.